Endothelial receptor tyrosine kinases (RTKs) and their signaling mechanisms are of interest because they may control tumor angiogenesis and thereby tumor growth. In this report we have examined activation of the signal transducers and activators of transcription (STATs) by the three known vascular endothelial growth factor receptors (VEGFR1-3), as well as by the endothelial Tie-1 and -2 receptors. We also studied signaling by the R849W mutant of Tie-2 (MTie-2), which has been shown to cause venous malformations. When overexpressed in 293T cells, MTie-2 activated STAT1 while the other endothelial RTKs failed to do so. In contrast, the three VEGFRs were strong activators of STAT3 and STAT5, suggesting that they activate only a speci®c subset of these signal transducers. STAT3 and STAT5 were also activated by Tie-2 and, more so, by MTie-2. Tyrosine phosphorylation and DNA binding of STATs correlated with their ability to activate transcription as judged by luciferase assays. When co-expressed with STAT5, VEGFR-1 as well as both the Tie-2 receptor forms increased expression of the cell cycle inhibitor p21. Interestingly, co-expression of the Tie-2 receptors with STAT1 resulted in appearance of a novel, p21 related transcript. Taken together, these ®ndings identify STAT proteins as novel targets for signal transduction by the endothelial RTKs, suggesting that they may be involved in the regulation of endothelial function.
Introduction
Endothelial receptor tyrosine kinases (RTKs) play a central role in the establishment and maintenance of the vascular system (reviewed by Hanahan, 1997) . The ®ve endothelial speci®c RTKs known to date can be divided into two families based on their structure. The VEGFRs 1-3 resemble platelet-derived growth factor receptors (PDGFRs) but contain seven instead of ®ve Ig-like loops in their extracellular domain (Pajusola et al., 1992; Shibuya et al., 1990; Terman et al., 1992) . Both VEGFR-1 (Flt1) and VEGFR-2 (KDR/Flk-1) are receptors for VEGF (DeVries et al., 1992; Millauer et al., 1993) , which is a major regulator of vascular growth and permeability (reviewed by Ferrara and Davis-Smyth, 1997) . In addition, VEGFR-1 binds PIGF and VEGF-B (Sawano et al., 1996; Olofsson et al., submitted) and VEGFR-2 binds VEGF-C/VRP and VEGF-D/FIGF (Achen et al., 1998; Joukov et al., 1996; Orlandini et al., 1996) . The third member of the family, VEGFR-3 (Flt4), binds selectively VEGF-C and VEGF-D (Achen et al., 1998; Joukov et al., 1996; Lee et al., 1996) and has been implicated in the growth of the lymphatic endothelium (Jeltsch et al., 1997; Kaipainen et al., 1995) . The second family of endothelial RTKs consists of Tie-1 and Tie-2 (Tek), which are characterized by a multidomain structure containing three extracellular epidermal growth factor (EGF) homology domains (Dumont et al., 1993; Partanen et al., 1992; Ziegler et al., 1993) . While the ligand for Tie-1 is yet to be identi®ed, two recently cloned proteins Ang-1 and Ang-2 have been shown to bind Tie-2 Maisonpierre et al., 1997) .
Inactivation of VEGFR-1, -2, Tie-1 and Tie-2 in mice by homologous recombination has indicated that while all four receptors are essential for normal vascular development, they serve dierent functions. VEGFR-2 is required for the initial development of endothelial and hemopoietic cells (Shalaby et al., 1995) and VEGFR-1 plays a role in the organization of the vasculature (Fong et al., 1995) . Tie-1 is required for long-range capillary sprouting during angiogenesis of ectodermally derived tissues and perhaps also for hemodynamic stress resistance and¯uid exchange across capillaries (Puri et al., 1995; Sato et al., 1995) , while Tie-2 may control the recruitment of and interaction with peri-endothelial support cells (Dumont et al., 1994; Sato et al., 1995) . The role of Tie-2 in smooth muscle cell recruitment is also suggested by the ®nding that an arginine-to-tryptophan mutation (R849W) in the kinase domain of this receptor in humans causes venous malformations characterized by large vessels lacking smooth muscle cells (Vikkula et al., 1996) .
Signaling mechanisms underlying the functional dierences between the endothelial RTKs remain largely unknown. VEGF has been reported to activate MAPK, p38, the PLC-g-PKC pathway and PI3K in dierent types of endothelial cells (Guo et al., 1995; Rousseau et al., 1997; Seetharam et al., 1995; Xia et al., 1996) but as these cells express more than one VEGFR type, it is not possible to attribute the results to a particular receptor. VEGFR-2 and VEGFR-3 have been shown to transduce mitogenic signals when ectopically expressed in NIH3T3 ®broblasts, while VEGFR-1 failed to do so (Pajusola et al., 1994; Seetharam et al., 1995; Takahashi and Shibuya, 1997) . Both VEGFR-1 and -2 were able to activate PLC-g, but MAPK activation was more pronounced in cells expressing VEGFR-2 (Seetharam et al., 1995; Takahashi and Shibuya, 1997) . Activation of MAPK in response to VEGF was much slower in NIH3T3-VEGFR-2 cells when compared to endothelial cells, suggesting involvement of cell type-speci®c signaling mechanisms . In contrast to the VEGFRs, signal transduction by the Tie family remains largely unknown. While there are no reports on Tie-1 signaling, the Tie-2 kinase domain has been shown to interact with SH-PTP2 and GRB2 but not PI3K or PLC-g (Huang et al., 1995) .
In this work we have investigated the ability of endothelial RTKs to activate signaling pathways involving the STAT proteins. The JAK-STAT pathway was initially discovered in interferon signaling and has since been implicated in signal transduction by numerous cytokine receptors (for recent reviews, see Darnell, 1997; Ihle, 1996) . Ligand-induced dimerization of cytokine receptors results in activation of JAK tyrosine kinases associated with them. JAKs can in turn phosphorylate the receptors, thus creating docking sites for signaling molecules such as STATs. STATs are latent cytoplasmic transcription factors which can speci®cally bind to tyrosine phosphorylated receptors via their SH2 domain. Recruited STATs get phosphorylated (presumably by JAKs) which enables them to dimerize, translocate to the nucleus and activate transcription through binding to GAS elements. To date at least seven dierent mammalian STATs have been cloned. However, the JAK-STAT pathway has turned out to be somewhat of a misnomer as STATs can be activated by other kinases, and JAKs may have other functions than STAT activation. Interestingly, receptor tyrosine kinases such as PDGFR and EGFR have been shown to activate STATs (Fu and Zhang, 1993; Silvennoinen et al., 1993) . Although both receptors also activate JAKs, the STAT activation is independent of JAKs and requires only the receptors' intrinsic kinase activity (Leaman et al., 1996; Vignais et al., 1996) .
Results
The Tie-2 receptor mutant associated with venous malformations activates STAT1
In order to investigate the ability of the VEGFRs and Tie receptors to activate STATs, they were coexpressed with STAT1, STAT3 or STAT5 in 293T cells by transient transfection. Under these conditions, RTK overexpression results in ligand-independent activation, thus allowing signal transduction also by the orphan receptor Tie-1 to be studied. STAT activation was initially studied by electrophoretic mobility shift assays (EMSA). As STATs need to be tyrosine phosphorylated and dimerized in order to bind DNA, EMSA provides a very sensitive method to monitor STAT activation. Nuclear extracts were prepared from 293T cells transfected with the endothelial RTKs together with STAT1 or STAT5 and analysed by EMSA using an oligonucleotide probe which contains the GAS site from the b-casein promoter (b-casein GAS).
As shown in Figure 1 (top panel), MTie-2 activated STAT1, while the other endothelial RTKs failed to do so, although very weak signals were occasionally observed after long exposures in extracts from cells transfected with VEGFR-2 and wild-type Tie-2. No bcasein GAS-binding activity was observed in cells transfected with the receptors alone (data not shown). As a positive control for STAT1 activation we used the non-receptor tyrosine kinase Bmx, which is able to activate STAT1, STAT3 and STAT5 (Saharinen et al., 1997) and which is expressed mainly in endothelial cells, hemopoietic progenitors and granulocytes/monocytes Kaukonen et al., 1996; Tamagnone et al., 1994; Weil et al., 1997) . STAT1 was expressed in all transfectants as judged by Western blotting of total cell lysates (Figure 1, lower panel) . The receptor expression and tyrosine phosphorylation was con®rmed by immunoprecipitation and Western blotting (Figure 2 ).
Activation of STAT3 and STAT5
In contrast to what was observed with STAT1, STAT5 was strongly activated by all three VEGFRs as judged by EMSA (Figure 3 , top panel). Also Tie-2 activated a low level of STAT5 DNA binding, and weak signals were occasionally detected also in cells transfected with Tie-1. Interestingly, MTie-2 was a much more potent activator of STAT5 than the wild-type receptor. This is consistent with the increased tyrosine kinase activity of the MTie-2 receptor expressed in a baculovirus system (Vikkula et al., 1996) . Immunoprecipitation and Western blotting of STAT5 con®rmed that STAT5 was expressed at equal levels in all transfectants ( Figure 3 , bottom panel), indicating that the differences observed were not due to dierent expression levels. Western blotting of the STAT5 immunoprecipitates using anti-phosphotyrosine antibodies indicated that the EMSA results correlated with STAT5 tyrosine phosphorylation ( Figure 3 , middle panel). Activation of STAT3 by the endothelial RTKs was analysed similarly by EMSA, except that an oligonucleotide containing the high anity STAT3 binding site SIE from the c-fos promoter was used as a probe. Again VEGFRs induced the highest level of activation, followed by the mutant and wild-type Tie-2, while the activation by Tie-1 was barely detectable ( Having established that VEGFRs can activate STAT proteins when overexpressed, we wanted to examine whether VEGF could induce STAT activation in primary human endothelial cells. Human umbilical vein endothelial cells (HUVEC) were stimulated with VEGF for 30 min and STAT activation was analysed by EMSA using the b-casein GAS and SIE oligonucleotide probes. As shown in Figure 5 , nuclear extracts from HUVEC stimulated with VEGF contained proteins that bound to the b-casein GAS, and this complex migrated similarly to activated STAT5 used as a control. In contrast, the HUVEC extracts did not exhibit any speci®c binding to the SIE probe (data not shown).
Endothelial RTKs stimulate the transcriptional activator function of STAT5
Although tyrosine phosphorylation of STATs is sucient for DNA binding, STAT-mediated transcriptional activation can require other modi®cations such as serine phosphorylation (Beadling et al., 1996; Wen et al., 1995) . In order to examine whether the endothelial RTKs can render STAT5 transcriptionally active, they were transfected into 293T cells together with a luciferase reporter construct containing a 344 bp fragment of the proximal b-casein promoter which has been shown to be STAT5 responsive (Gouilleux et al., 1994). All transfections included a constitutive TKrenilla luciferase construct used as an internal control (see Materials and methods). As shown in Figure 6 , the reporter was not signi®cantly activated by expression of STAT5 alone. However, when STAT5 was coexpressed with VEGFRs, the reporter activity was increased over 50-fold. In keeping with the EMSA results, Tie-1 increased the reporter activity only twofold and Tie-2 caused an intermediate level of activation. The luciferase activity induced by MTie-2 was comparable to that of the VEGFRs, indicating that this mutant is capable of providing all the signals required to convert STAT5 to a transcriptionally active form. In all cases the reporter activation was mediated by STAT5 as omitting it from the transfection abolished the inducibility (data not shown).
p21 expression is induced by VEGFR-1 and Tie-2 STAT1 and STAT5 have recently been implicated in the induction of the cell cycle inhibitor p21 by IFN-g and thrombopoietin, respectively (Chin et al., 1996; Matsumura et al., 1997) . In order to investigate whether STAT activation by endothelial RTKs also leads to p21 induction, we analysed p21 mRNA expression by Northern blotting in 293T cells cotransfected with STATs and the receptors. As shown in Figure 7 (upper panel), VEGFR-1 increased p21 mRNA expression when co-transfected with STAT5. Phosphorimager quantitation of the Northern blot indicated that the p21 mRNA level was increased by 30% when compared to cells transfected with STAT5 alone. p21 mRNA levels were increased also in cells expressing STAT5 and Tie-2. The mutant receptor was sixfold more potent than the wild-type in this regard, increasing p21 mRNA by 130%. The increase of p21 mRNA was dependent on STAT5, as omitting the STAT5 expression vector from the transfection abolished the induction (data not shown). When the Tie-2 receptors were co-transfected with STAT1, p21 mRNA was not signi®cantly increased but, interestingly, a p21-hybridizing transcript with faster mobility appeared. This mRNA species was faintly visible in cells transfected with STAT1 alone, but it was induced 3.0-fold and 4.3-fold in cells transfected with wild-type and mutant Tie-2, respectively. The appearance of the shorter transcript was strictly dependent on the coexpression of STAT1, as it was not observed in cells transfected with the receptors alone (data not shown) or together with STAT5. To ensure that the samples Figure 5 VEGF induces b-casein GAS binding activity in primary human endothelial cells. HUVEC were stimulated with 50 ng/ml VEGF for 30 min or left unstimulated, and nuclear extracts prepared and analysed by EMSA using the b-casein GAS oligonucleotide probe. Also shown are control extracts containing activated STAT5 or STAT1 as indicated Figure 6 Endothelial RTKs stimulate the transcriptional activator function of STAT5. 293T cells were transfected with b-casein ®re¯y luciferase reporter construct and STAT5 expression vector together with expression vectors for the endothelial RTKs as indicated. Cell lysates were analysed for STAT5-dependent luciferase activity using the dual luciferase system as described in Materials and methods, and the values were normalized for the Renilla luciferase activity used as an internal control + RNA was prepared and 8 mg samples were analysed by Northern blotting using p21 cDNA probe (upper panel). Signals corresponding to the p21 mRNA and to the novel, p21-related transcript designated as`X' are shown. The ®lter was stripped and re-probed for b-actin to con®rm equal RNA loading (lower panel) contained equal amounts of RNA, the ®lters were stripped and re-probed for b-actin (Figure 7 , lower panel).
Discussion
In this report we show evidence that STATs are potential targets for signal transduction by the endothelial RTKs of the VEGFR and Tie families. The three known VEGFRs strongly activated STAT3 and STAT5 but, in contrast to the known STATactivating RTKs such as the PDGFR and EGFR, failed to activate STAT1. Also Tie-2 could weakly activate both STAT3 and STAT5, while activation by Tie-1 was barely detectable. Interestingly, the R849W mutant of Tie-2, which has been shown to be responsible for venous malformations in humans showed a distinct STAT activation response: not only was it more potent than the wild-type receptor in activating STAT3 and STAT5, but it also was able to activate STAT1. The induced DNA binding of STATs correlated with their ability to activate transcription as judged by a luciferase assay, indicating that the endothelial RTKs are able to provide all the necessary signals to render STATs transcriptionally active. In keeping with this, VEGFR-1 and Tie-2 increased expression of the cell cycle inhibitor p21 mRNA in a STAT5-dependent manner. Interestingly, the wild-type and the mutant Tie-2 also induced the expression of a novel, shorter transcript hybridizing with the p21 probe. To our knowledge this is the ®rst demonstration of STAT activation by the endothelial RTKs and the ®rst report on potential downstream eectors linking mutant Tie-2 to the pathology of the venous malformations.
The spectrum of STAT activation by VEGFRs was more restricted than that of the PDGFR, which has been shown to activate STATs 1, 3, 5 and 6 (Fu and Zhang, 1993; Patel et al., 1996; Silvennoinen et al., 1993; Valgeirsdottir et al., 1998) . The speci®city of STAT recruitment by cytokine receptors is based on the ability of the SH2 domains of dierent STATs to speci®cally recognize distinct receptor phosphotyrosine motifs (Stahl et al., 1995) . May et al. (1996) have demonstrated that ecient STAT5 recruitment requires the consensus YZXZ in which Z stands for a hydrophobic amino acid with an aliphatic side chain, preferably leucine or isoleucine. Interaction was further enhanced by the presence of an acidic residue in position -1 or -2. Tyrosines 794 (DYLSI) and 1169 (DYIPI) in the cytoplasmic domain of VEGFR-1 perfectly match this consensus, and the latter has been shown to be an autophosphorylation site (Sawano et al., 1997) . Both tyrosine residues are conserved in VEGFR-2 (799: GYLSI and 1173: DYIVI), and the ®rst tyrosine can be found also in the membraneproximal region of VEGFR-3 (812: GYLSI). Mutational analysis will be required to con®rm whether these tyrosine residues are indeed involved in STAT5 activation by VEGFRs, but it should be noted that a similar tyrosine residue in the membrane proximal region of PDGFR (579: EYIYV) has been recently implicated in STAT5 activation (Valgeirsdottir et al., 1998) . Peptide sequences matching the STAT3 consensus YXXQ (Stahl et al., 1995) can be also found in all the endothelial RTKs except Tie-1: 1017(YSFQ) and 1041(YTTQ) in VEGFR-3, 1006(YSFQ) and 1080(YTIQ) in VEGFR-2, 1002(YSFQ) in VEGFR-1, and 954(YLSQ) in Tie-2. However, all these tyrosine residues are located in the kinase domain and are hence less likely to participate in receptor-STAT interactions. It is noteworthy that PDGFR which also activates STAT3 lacks this recognition motif, suggesting that these RTKs may use alternative ways to recruit STAT3.
Mechanisms of STAT activation by endothelial RTKs remain to be elucidated. It has been shown that although PDGFR and EGFR mediate JAK activation, their ability to activate STATs is independent of individual JAKs and requires only the receptors' intrinsic kinase activity (Leaman et al., 1996; Vignais et al., 1996) . Preliminary results with a mutant VEGFR-3 lacking the tyrosine kinase domain suggests that the same may apply also to the endothelial RTKs (unpublished observations of the authors). It has been recently shown that the cytoplasmic tyrosine kinase Bmx which is expressed in cells of endothelial and hemopoietic origin Kaukonen et al., 1996; Tamagnone et al., 1994; Weil et al., 1997 ) is able to activate STATs, including STAT3 and STAT5 (Saharinen et al., 1997) . Although Bmx is not likely to play a role in STAT activation by the transfected endothelial RTKs in 293T cells, it would be of interest to examine whether it is activated by these receptors in endothelial cells.
In an attempt to identify possible target genes for the STATs activated by the VEGFRs and Tie receptors we studied expression of the cell cycle inhibitor p21. p21 has been recently shown to be induced by interferon-g activated STAT1 and thrombopoietin activated STAT5, and these signals were implicated in growth inhibition and megakaryocyte dierentiation, respectively (Chin et al., 1996; Matsumura et al., 1997) . STAT1-mediated p21 induction is likely to be involved also in growth retardation by the constitutively active TDII mutant of ®broblast growth factor receptor-3 which causes the most common form of dwar®sm in humans (Su et al., 1997) . We found that while all three VEGFRs activated STAT5, only VEGFR-1 was able to induce the expression of p21. It is possible that STAT5 activation is necessary but not sucient for p21 induction and that only VEGFR-1 is able to provide the other signal(s) required. On the other hand, VEGFR-2 and -3 may induce negative regulators of the p21 promoter which overcome the activation by STAT5. It is tempting to speculate that the diculties in establishing VEGFR-1-expressing cell lines (Seetharam et al., 1995) would be due to the ability of this receptor to induce p21. However, the outcome of STAT signaling is clearly determined by its integration with other signal transduction pathways activated. Tie-2 also induced p21 expression in a STAT5-dependent manner and the MTie-2 was stronger in this regard. When these receptors were co-expressed with STAT1, the level of p21 was not signi®cantly increased but, interestingly, a shorter transcript recognized by the p21 probe appeared. The identity of this mRNA species is currently unknown, but its expression is clearly dependent on STAT1 as it was not detected in cells expressing STAT5 and Tie-2. The fact that also wild-type Tie-2 could induce this transcript indicates that the threshold level of STAT1 activation required is likely to be rather low. Although shorter p21 transcripts have not been previously reported, truncated forms of p21 protein are known to exist (Poon and Hunter, 1998; Tchou et al., 1996) . However, they are thought to result from proteolytic processing rather than alternative splicing (Tchou et al., 1996) . The observed induction of both the 2.1 kb and the shorter transcript hybridizing with the p21 cDNA probe by the endothelial RTKs is likely to be p53-independent, as the 293T cells used in these experiments express both adenovirus E1B and SV40 largeT proteins which can inactivate p53 (Ko and Prives, 1996) .
The biological role of STAT activation by endothelial RTKs is not known at present. No vascular defects have been reported in mice lacking STAT5A or STAT5B (Liu et al., 1997; Udy et al., 1997) , although it is possible that such eects would be masked by the redundant action of STAT3. The knockout of STAT3, on the other hand, is embryonic lethal resulting in death around E7 (Takeda et al., 1997) . As the expression of VEGFRs and Tie receptors begins at that time point or later, it is not possible to analyse what eects STAT3 de®ciency would have on signaling by these receptors. Of note, STAT3 has been recently shown to be required for HGF-induced branching morphogenesis of epithelial cells (Boccaccio et al., 1998) . Whether STAT3 is also involved in tube formation signalled by endothelial RTKs remains to be investigated. It will also be of interest to further characterize the novel, p21-related transcript and analyse its expression, as well as that of p21 itself, in endothelial cells from venous malformations associated with the mutant Tie-2.
Materials and methods

Reagents
The polyclonal antibody (Ab) against VEGFR-3 (707) and the monoclonal antibodies (mAbs) against Tie-1 (8G3 and 4B2) have been described previously (Batard et al., 1996) . The antiserum against the 32 carboxy-terminal amino acids of Tie-2/Tek (819) and the anti-KDR Ab (r212) were kind gifts from Drs Juha Partanen, Panu Mentula and Herbert Weich, respectively. The polyclonal antibodies against VEGFR-1 (sc-316), STAT5 (sc-835) and STAT3 (sc-482) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-FLAG mAb (M2) was purchased from the Eastman Kodak Company (New Haven, CT, USA) and the anti-phosphotyrosine mAb (4G10) was from Upstate Biotechnology (Lake Placid, NY, USA). Recombinant human (rh) VEGF was purchased from R&D Systems (Abingdon, UK).
DNA constructs
For receptor expression constructs the cDNAs for hVEGFR-1, hVEGFR-3, hTie-1 and hTie-2 were cloned into pcDNA3.1Z+ (Invitrogen). The R849W mutant of Tie-2 was generated by the Gene editor in vitro sitedirected mutagenesis system (Promega). The expression plasmid pCI-Neo-Bmx-HA has been described previously (Saharinen et al., 1997) . Renilla luciferase expression vector pRL-TK was from Promega. Luciferase reporter construct b-casein (7344/71)Luc (Gouilleux et al., 1994) and expression plasmids for STAT5A, FLAG-tagged STAT1, STAT3 and VEGFR-2 were kind gifts from Drs Berndt Groner, Chris Schindler, James Darnell and Bruce Terman, respectively and have been previously described.
Cell culture and transfections
293T cells were grown in DMEM supplemented with 10% fetal calf serum (GIBCO ± BRL, Life Technologies, Gaithersburg, MD, USA), glutamine and antibiotics. Cells were transfected using the calcium phosphate method and harvested 72 h after transfection for EMSA, immunoprecipitation and Western blotting, and after 48 h for luciferase assays and Northern blotting.
HUVEC were isolated from umbilical cords (Jae et al., 1973) and cultured in M199 medium containing Earle's Salts (HyClone, Logan, UT, USA), 10% fetal calf serum, 25 mg/ml endothelial cell growth supplement (Upstate Biotechnology, Lake Placid, NY, USA) and heparin (Sigma) at 378C in a 5% CO 2 atmosphere. HUVEC were used between passages 2 and 5.
Nuclear extraction and electrophoretic mobility shift assay
For nuclear extracts, cells were trypsinized, washed with PBS, and resuspended in PSB lysis buer (50 mM HEPES pH 7.5, 100 mM NaF, 10 mM Na 4 P 2 O 7 , 2 mM Na 2 VO 4 , 2 mM Na 2 MoO 4 , 2 mM EDTA) containing 0.2% NP40, 10 mM MgCl 2 , 10 mg/ml aprotinin, 2 mg/ml leupeptin and 2 mM Pefabloc (Boehringer Mannheim). After 1 min on ice, the nuclei were pelleted and washed in the same buer without NP40. The nuclei were again pelleted and then extracted with vigorous agitation at 48C in PSB containing 0.1% NP40, 0.3 M NaCl, 10% glycerol and protease inhibitors as above. Protein determinations were carried out on nuclear extracts using the BCA reagent (Pierce Chemicals, Rockford, IL, USA) according to manufacturer's instructions.
Mobility shift assays were performed using doublestranded oligonucleotides corresponding to the GAS site in the b-casein promoter (5'-AGATTTCTAGGAATT-CAAATCC-3') or the sis-inducible element (SIE) in the c-fos promoter (5'-AATTCAGCATTTCCCGTAAATC-CCTCCG-3'). The probes were labeled by end-®lling 2 pmol of ds oligonucleotide with overhanging 5' ends using Klenow, 0.1 mM dGTP/dATP/dTTP and 50 mCi [a 32 P]dCTP. Binding reactions were carried out in a total volume of 15 ml in the following buer: 10 mM Tris-HCl pH 8.0, 100 mM NaCl, 5 mM MgCl 2 , 1 mM DTT, 0.5 mg/ml BSA, 10% glycerol. Each reaction, also containing 1 mg of poly(dI-dC) and 30 fmol of 32 P-labeled probe, was initiated by the addition of 2 mg of nuclear extract. The reactions were incubated at room temperature for 30 min prior to electrophoretic analysis on a 5% polyacrylamide gel in 0.256TBE buer.
Luciferase assay
For luciferase assays, cells were transfected with the bcasein (7344/71) luciferase reporter construct together with STAT and receptor expression constructs as described in the text. All the transfections included the constitutively active Renilla luciferase expression vector pRL-TK (Promega) as an internal control. Cells were lysed in Passive lysis buer (Promega) and the luciferase activity was determined using the Dual-luciferase reporter assay system (Promega) according to manufacturer's instructions. The reporter-driven ®re¯y luciferase activity was normalized to the Renilla luciferase activity to correct for transfection eciency and protein content of the lysates.
Immunoprecipitation and Western blotting
For immunoprecipitation and Western blotting the cells were lysed in Triton lysis buer (50 mM HEPES pH 7.5, 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl 2 , 100 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM EGTA, 2 mM Na 2 VO 4 ) supplemented with PMSF and aprotinin. The lysates were cleared by centrifugation and incubated with antibodies as indicated in the text for 2 h on ice. Protein A or G Sepharose was then added and the incubation continued for 30 min. The Sepharose beads were collected by centrifugation and washed three times in the lysis buer prior to boiling in Laemmli sample buer. Immunoprecipitates or total cell lysates were separated on SDS ± PAGE and transferred to nitrocellulose (Schleicher & Schuell) . Immunodetection was performed using speci®c primary antibodies as described in the text, followed by biotinylated anti-mouse secondary antibody (DAKO, Denmark) and streptavidinbiotin-HRP conjugate (Amersham Life Sciences, UK), or directly HRP-conjugated anti-rabbit or anti-mouse antibodies (DAKO, Denmark). The bands were visualized by the enhanced chemiluminescence (ECL) method.
RNA isolation and Northern blot analysis
Poly(A) + RNA was isolated by binding to oligo(dT) cellulose (Boehringer Mannheim) and 8 mg samples were size-fractionated on 1.0% formaldehyde-agarose gels, transferred to Hybond-N nylon membrane (Amersham Life Sciences, UK), UV cross-linked and hybridized with p21 cDNA probe corresponding to the coding sequence of human p21 (a kind gift from Dr Bert Vogelstein). Human b-actin cDNA probe was used as an internal control for equal loading. The probes were labeled with a 32 P-dCTP (3000 Ci/mmol; Amersham) by random priming. Prehybridizations and hybridizations were performed at 428C in a solution containing 50% formamide, 56Denhardt solution, 56SSPE, 0.5% SDS and 200 mg/ml salmon sperm DNA. Filters were washed once for 30 min at room temperature and twice for 10 min at 658C with 16SSC, 0.1% SDS, and exposed to Fuji Medical X-ray ®lm after quantitation by phosphorimager analysis (Bio-Imaging Analyser BAS1500, Fuji).
